Patrick A. Flume
Impact in
- Pulmonary and Respiratory Medicine top 0.05%
- Cystic Fibrosis Research Advances
- Inhalation and Respiratory Drug Delivery
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Speech and Hearing top 0.5%
- Adolescent and Pediatric Healthcare
Papers in
-
- Cystic Fibrosis Research Advances 188
- Inhalation and Respiratory Drug Delivery 8
- Epidemiology 27
- Mycobacterium research and diagnosis 26
- Co-authors
- J. Stuart Elborn (21 shared papers)Bruce C. Marshall (9 shared papers)Karen Robinson (5 shared papers)Peter J. Mogayzel (6 shared papers)Christopher Hooper Goss (23 shared papers)Randall L. Rosenblatt (3 shared papers)Donald R. VanDevanter (43 shared papers)Kenneth N. Olivier (4 shared papers)
- Journals
- Journal of Cystic Fibrosis (95 papers)CHEST Journal (19 papers)American Journal of Respiratory and Critical Care Medicine (17 papers)Annals of the American Thoracic Society (9 papers)Pediatric Pulmonology (7 papers)
- Partner nations
- United StatesUnited KingdomAustralia
In The Last Decade
Patrick A. Flume
260 papers receiving 13.3k citations
Patrick A. Flume's Hit Papers
Peers
Comparison fields: 5 of 146
- Pulmonary and Respiratory Medicine 10.2k
- Speech and Hearing 246
- Applied Microbiology and Biotechnology 115
- Endocrinology 116
- Pharmacology 410
Countries citing papers authored by Patrick A. Flume
This map shows the geographic impact of Patrick A. Flume's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick A. Flume with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick A. Flume more than expected).
Fields of papers citing papers by Patrick A. Flume
This network shows the impact of papers produced by Patrick A. Flume. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick A. Flume. The network helps show where Patrick A. Flume may publish in the future.
Co-authors
The 25 scholars most cited alongside Patrick A. Flume, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 272 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR Hit paper breakdown → | 2015 | 1375 |
| 2 | Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial Hit paper breakdown → | 2019 | 1083 |
| 3 | Cystic Fibrosis Pulmonary Guidelines Hit paper breakdown → | 2007 | 847 |
| 4 | Cystic Fibrosis Pulmonary Guidelines: Treatment of Pulmonary Exacerbations Hit paper breakdown → | 2009 | 589 |
| 5 | ECFS best practice guidelines: the 2018 revision Hit paper breakdown → | 2018 | 565 |
| 6 | European Cystic Fibrosis Society Standards of Care: Best Practice guidelines Hit paper breakdown → | 2014 | 434 |
| 7 | Treatment of lung infection in patients with cystic fibrosis: Current and future strategies Hit paper breakdown → | 2012 | 398 |
| 8 | Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity Hit paper breakdown → | 2018 | 379 |
| 9 | Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research Hit paper breakdown → | 2017 | 325 |
| 10 | 2010 | 276 | |
| 11 | Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study Hit paper breakdown → | 2018 | 275 |
| 12 | 2012 | 262 | |
| 13 | 2017 | 247 | |
| 14 | 2009 | 231 | |
| 15 | 2002 | 227 | |
| 16 | 2016 | 216 | |
| 17 | 2015 | 193 | |
| 18 | 2014 | 192 | |
| 19 | 2010 | 186 | |
| 20 | 1994 | 148 |
About Patrick A. Flume
Patrick A. Flume is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology, Pharmacology, Emergency Medical Services and Infectious Diseases, having authored 272 papers that have together received 13.9k indexed citations. Recurring topics across this work include Cystic Fibrosis Research Advances (188 papers), Mycobacterium research and diagnosis (26 papers), Antibiotics Pharmacokinetics and Efficacy (9 papers), Inhalation and Respiratory Drug Delivery (8 papers), SARS-CoV-2 and COVID-19 Research (6 papers), Ethics in Clinical Research (5 papers), Transplantation: Methods and Outcomes (4 papers) and Central Venous Catheters and Hemodialysis (4 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (10.2k citations), Speech and Hearing (246 citations), Applied Microbiology and Biotechnology (115 citations), Endocrinology (116 citations) and Pharmacology (410 citations). Patrick A. Flume has collaborated with scholars based in United States, United Kingdom and Australia. Frequent co-authors include J. Stuart Elborn, Bruce C. Marshall, Karen Robinson, Peter J. Mogayzel, Christopher Hooper Goss, Randall L. Rosenblatt, Donald R. VanDevanter, Kenneth N. Olivier, James Duncan Chalmers and David E. Geller. Their work appears in journals such as Journal of Cystic Fibrosis, CHEST Journal, American Journal of Respiratory and Critical Care Medicine, Annals of the American Thoracic Society and Pediatric Pulmonology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.